Pasireotide LAR in patients with metastatic carcinoid tumors: Interim safety results from a randomized, multicenter phase I study

被引：0
|
作者：
Wolin, E. [1 ]
Kvols, L. [2 ]
Ezzat, S. [3 ]
Kocha, W. [4 ]
Van Cutsern, E. [5 ]
Schonherr, U. [6 ]
Fandi, A. [7 ]
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[3] Univ Toronto, Ontario Canc Inst, Toronto, ON M5S 1A1, Canada
[4] London Reg Canc Ctr, London, ON N6A 4L6, Canada
[5] Univ Hosp Gasthuisberg, Digest Oncol Unit, B-3000 Leuven, Belgium
[6] Novartis Pharma AG, Basel, Switzerland
[7] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [31] A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer
    Bauman, Julie E.
    Chen, Zhengjia
    Zhang, Chao
    Ohr, James P.
    Ferris, Robert L.
    McGorisk, Gerald M.
    Brandt, Stephen
    Srivatsa, Sumathi
    Chen, Amy Y.
    Steuer, Conor E.
    Shin, Dong M.
    Saba, Nabil F.
    Khuri, Fadlo R.
    Owonikoko, Taofeek K.
    CANCERS, 2022, 14 (11)
  • [32] Safety and Efficacy of Pasireotide LAR (PAS) in Patients with Advanced Neuroendocrine Tumors (NET): Findings of a Phase I, Multi-Center, Open-Label, Dose-Escalation Study
    Yao, J.
    Chan, J.
    Mita, A.
    Kundu, M.
    Valera, S. Z.
    Unge, P.
    Strosberg, J.
    Wolin, E.
    NEUROENDOCRINOLOGY, 2016, 103 : 76 - 76
  • [33] Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors
    Varker, Kimberly A.
    Campbell, Jacqueline
    Shah, Manisha H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (04) : 661 - 668
  • [34] Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors
    Kimberly A. Varker
    Jacqueline Campbell
    Manisha H. Shah
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 661 - 668
  • [35] Preliminary safety, pharmacokinetics, and efficacy results from an open-label, multicenter, Phase I/II study of avapritinib in Chinese patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).
    Li, Jian
    Gong, Jifang
    Wang, Xicheng
    Li, Jie
    Li, Yan
    Qi, Changsong
    Shen, Lin
    Ren, Wenxiao
    Zhao, Wanqi
    Wang, Yedong
    Hu, Jin
    Ren, Chunli
    Song, Wenjie
    Yang, Jianxin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II Trial
    Petersenn, S.
    Schopohl, J.
    Barkan, A.
    Mohideen, P.
    Colao, A.
    Abs, R.
    Buchelt, A.
    Ho, Y. -Y.
    Hu, K.
    Farrall, A. J.
    Melmed, S.
    Biller, B. M. K.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (06): : 2781 - 2789
  • [37] Pasireotide Long Acting Release (LAR) in Breast Cancer Patients To Prevent Lymphocele after Mastectomy and Axillary Node Dissection: A Randomized, Multicenter, Phase II Study.
    Chereau, E.
    Uzan, C.
    Bezu, C.
    Mazouni, C.
    Ballester, M.
    Gouy, S.
    Rimareix, F.
    Garbay, J-R
    Darai, E.
    Uzan, S.
    Coutant, C.
    Rouzier, R.
    CANCER RESEARCH, 2011, 71
  • [38] Phase I, Multi-center, Open-label, Dose-escalation Study of Pasireotide LAR (PAS) in Patients With Advanced Neuroendocrine Tumors (NET)
    Strosberg, Jonathan
    Chan, Jennifer
    Mita, Alain
    Kundu, Madan
    Hermosillo, Karina
    Hu, Ke
    Wolin, Edward
    Yao, James
    PANCREAS, 2017, 46 (03) : 437 - 437
  • [39] Phase I, multi-center, open-label, dose-escalation study of pasireotide LAR (PAS) in patients with advanced neuroendocrine tumors (NET)
    Strosberg, Jonathan R.
    Chan, Jennifer A.
    Mita, Alain C.
    Kundu, Madan
    Valera, Sue-zette
    Unge, Peter
    Darstein, Christelle
    Hu, Mike
    Wolin, Edward M.
    Yao, James C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE IN ACROMEGALY WITH PASIREOTIDE LAR AND OCTREOTIDE LAR: RESULTS FROM A LARGE, RANDOMIZED, DOUBLE-BLIND PHASE III TRIAL
    Badia, X.
    Forsythe, A.
    Nelson, L. M.
    Coles, T. M.
    Mcleod, L. D.
    Webb, S. M.
    VALUE IN HEALTH, 2012, 15 (07) : A505 - A505
12345